These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18544990)

  • 1. Secondary hormonal manipulation.
    Merseburger AS; Belka C; Behmenburg K; Stenzl A
    Front Radiat Ther Oncol; 2008; 41():93-102. PubMed ID: 18544990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?].
    Schilling D; Küfer R; Kruck S; Stenzl A; Kuczyk MA; Merseburger AS
    Urologe A; 2008 Oct; 47(10):1334-8. PubMed ID: 18566791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hormonal manipulations in prostate cancer.
    Ryan CJ; Small EJ
    Curr Oncol Rep; 2005 May; 7(3):228-33. PubMed ID: 15847715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current topics and perspectives relating to hormone therapy for prostate cancer.
    Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
    Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
    Paul R; Breul J
    Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selection of hormonal therapy in prostate cancer: who, when, and for how long?
    Ryan CJ; Small EJ
    J Natl Compr Canc Netw; 2004 May; 2(3):261-8. PubMed ID: 19795609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
    Small EJ; Vogelzang NJ
    J Clin Oncol; 1997 Jan; 15(1):382-8. PubMed ID: 8996165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary hormonal manipulation of prostate cancer.
    Small EJ; Harris KA
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):24-30. PubMed ID: 12198635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation.
    Schmid HP; Keuler FU; Altwein JE
    Urol Int; 2007; 79(2):95-104. PubMed ID: 17851276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary hormonal manipulations in the management of advanced prostate cancer.
    Chaudhary UB; Rashid MH; Onitilo AA; Bissada NK
    Can J Urol; 2005 Jun; 12(3):2666-76. PubMed ID: 16011813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 18. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
    Mydin AR; Dunne MT; Finn MA; Armstrong JG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.